The first jab to be produced for RSV.
NEW RSV VACCINE
A team of Australian researchers are nearing the end of a 20-year project to create the world’s first vaccine for respiratory syncytial virus (RSV), in what is being called a “breakthrough”.
The research, published in the Lancet Infectious Diseases journal on Wednesday, revealed an effective, long-lasting monoclonal antibody treatment for babies called Nirsevimab.
Nirsevimab is expected to be submitted to regulatory bodies, including Australia’s Therapeutic Goods Administration and the Australian Technical Advisory Group on Immunisation, for approval in 12 months.
Followed closely by a maternal vaccine given in pregnancy to give newborns ‘protection against RSV’.
Peter Richmond, head of the Vaccine Trials Group and the School of Paediatrics at the University of Western Australia, said Niversimab had just gone through phase three clinical trials with positive results.
“It is expected to be licensed for use as the very first RSV prevention treatment in the United States and Europe by late 2022 or early 2023,” he said.
RSV is infects the airways and lungs and can lead to life-threatening complications, such as bronchiolitis and pneumonia. It is reportedly responsible for more than 100,000 deaths each year.
However, only roughly 6000 young children are admitted to hospital with RSV in Australia every year.
Attempts to develop an RSV vaccine have proved unsuccessful with efforts going back over 50 years.
This is due both to the difficulty of immunising very young infants, who often respond inadequately to vaccinations, and past experimental vaccines triggering more serious infections, delaying progress.
It’s the first of nine experimental vaccines and prophylactic drugs emerging from the final stage of testing before they can be licensed for use against RSV.
The vaccine couldn’t come at a ‘better time’, as new RSV spikes are being witnessed in Australia.
RECENT AUSTRALIAN SPIKE
Respiratory syncytial virus (RSV) infection is the most common cause of bronchiolitis and pneumonia among infants under 1 year of age.
In late 2020, while we were all focused on COVID, a RSV outbreak was reported, beginning in spring, and extending into summer across New South Wales, Australian Capital Territory, and Western Australia.
Queensland Health also saw a rise in the number of RSV cases in aged care in 2021.
University of Sydney researchers recently explored how the pandemic was responsible for creating a huge change in the incidence and genetics of RSV across the country:
That’s right, the pandemic (specifically lockdowns) have disrupted the seasonal pattern of RSV.
Yet another point to add to the infinite list of reasons detailing why lockdowns did more harm than good, on top of increased mental health issues, economic turmoil and social division.
Now, in August 2022, there is another spike occurring, this time in South Australia, as RSV reportedly rips through childcare centres and causes alarms with SA Health.
But thankfully, for the first time ever, a vaccine is on the way to ‘save the day’.
Is this yet another example of ‘problem, reaction, solution’ being witnessed?
What effects will this new vaccine have on mothers and babies already exposed to a lengthy list of concerning vaccines under the current Australian schedule?
Let’s not forget about the plethora of new COVID-19 vaccines that are set to touch down as well.
At every turn, there is a vaccine for every ailment or illness.
Ailments and illnesses largely created by the same people offering the cure.
Remember a world where injections weren’t required for absolutely everything?
The Clown World rolls on, folks.
For more TOTT News:
Facebook — Facebook.com/TOTTNews
YouTube — YouTube.com/TOTTNews
Instagram — Instagram.com/TOTTNews
Twitter — Twitter.com/EthanTOTT
Bitchute — Bitchute.com/TOTTNews
Gab — Gab.com/TOTTNews